{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T19:21:30Z","timestamp":1758050490878,"version":"3.44.0"},"reference-count":4,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.bulcan.2022.07.010","type":"journal-article","created":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T07:22:19Z","timestamp":1664004139000},"page":"1105-1106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Nouvelle AMM\u00a0: mosunetuzumab \u2013 traitement du lymphome folliculaire en troisi\u00e8me ligne"],"prefix":"10.1016","volume":"109","author":[{"given":"Camille","family":"Gondran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lo\u00efc","family":"Ysebaert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2022.07.010_bib0025","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/ajh.25696","article-title":"Follicular lymphoma: 2020\u00a0update on diagnosis and management","volume":"95","author":"Freedman","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bulcan.2022.07.010_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.bulcan.2022.07.003","article-title":"Nouvelles AMMs: Cellules CAR-T Tisagenlecleucel et Axicabtagene ciloleucel\u2013Lymphome folliculaire en 3\u00e8me et 4\u00e8me ligne","author":"Cordeil","year":"2022","journal-title":"Bull Cancer"},{"key":"10.1016\/j.bulcan.2022.07.010_bib0035","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.21.00931","article-title":"Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study","volume":"40","author":"Budde Lihua","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2022.07.010_bib0020","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1182\/blood-2021-145872","article-title":"Mosunetuzumab monotherapy is an effective and well-tolerated treatment option for patients with relapsed\/refractory (R\/R) follicular lymphoma (FL) who have received\u2265 2\u00a0prior lines of therapy: pivotal results from a phase I\/II study","volume":"138","author":"Budde","year":"2021","journal-title":"Blood"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455122003101?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455122003101?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:36:17Z","timestamp":1757792177000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455122003101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":4,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0007455122003101"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2022.07.010","relation":{},"ISSN":["0007-4551"],"issn-type":[{"type":"print","value":"0007-4551"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nouvelle AMM\u00a0: mosunetuzumab \u2013 traitement du lymphome folliculaire en troisi\u00e8me ligne","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2022.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer.","name":"copyright","label":"Copyright"}]}}